Belvedere Trading’s Tvardi Therapeutics TVRD Stock Holding History

Belvedere Trading’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-61	Closed	-$48K	–	461
2021 Q1	$48K	Buy	+61	New	+$41.8K	﹤0.01%	234

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Belvedere Trading's TVRD Position: Q2 2021 in Review

Belvedere Trading sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 61 shares — an estimated $48K sold.

Belvedere Trading first reported a position in TVRD in Q1 2021 and held it in 1 quarter. The position peaked at $48K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

Belvedere Trading reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
Belvedere Trading sold 61 Tvardi Therapeutics shares in Q2 2021, an estimated $48K.
Belvedere Trading first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 1 quarter.
Belvedere Trading's Tvardi Therapeutics position peaked at $48K in Q1 2021.
173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Belvedere Trading's 13F filing for Q2 2021, filed 23 Jul 2021.